Drug | Tablet
Linagliptin 5 mg
Type 2 diabetes mellitus: used to improve blood sugar control in adults, as monotherapy or in combination with other antidiabetic medicines along with diet and exercise.
Linagliptin is a DPP-4 inhibitor that increases incretin hormones (GLP-1, GIP) by preventing their breakdown. This increases insulin release in a glucose-dependent manner and reduces glucagon secretion, lowering blood glucose with a low risk of hypoglycaemia when used alone.
Oral tablet: typically 1 tablet (5 mg) once daily, with or without food, at the same time each day. Swallow whole with water; continue diet and exercise as advised. Dose adjustments may be needed when used with insulin or sulfonylureas to reduce hypoglycaemia risk.
Common side effects of Trajenta 5 Tablet may include:
Not for type 1 diabetes or diabetic ketoacidosis. Use caution in patients with history of pancreatitis; stop and seek medical help if severe persistent abdominal pain occurs. Rare serious hypersensitivity reactions (angioedema, anaphylaxis) and severe skin reactions (bullous pemphigoid) may occur; discontinue if suspected. Monitor for joint pain and signs of heart failure when used with other agents as clinically indicated. In renal impairment, linagliptin generally does not require dose adjustment; follow prescriber advice.
